Molecular markers for colon diagnosis, prognosis and targeted therapy

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 96-102

  Herzig, Daniel O ^a   Tsikitis, Vassiliki L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

BRAF V600E; KRAS; MSI; PI3K; TP53

Indexed keywords

APC PROTEIN; B RAF KINASE; BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 18Q; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; HUMAN; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; REVIEW; UNITED STATES; COLONIC NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PROGNOSIS;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920133637     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23806     Document Type: Review

References (131)

1. Siegel R, Ma J, Zou Z, Jemal A: Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
3. Deschoolmeester V, Baay M, Specenier P, et al.: A review of the most promising biomarkers in colorectal cancer: One step closer to targeted therapy. Oncologist 2010;15:699-731.
4. Pino MS, Chung DC: The chromosomal instability pathway in colon cancer. Gastroenterology 2010;138:2059-2072.
5. Lynch HT, Smyrk T, Lynch JF: Molecular genetics and clinicalpathology features of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome): Historical journey from pedigree anecdote to molecular genetic confirmation. Oncology 1998;55: 103-108.
6. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
7. Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993;260: 812-816.
8. Boland CR, Goel A: Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-2087e2073.
9. Toyota M, Ahuja N, Ohe-Toyota M, et al.: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
10. Shen L, Toyota M, Kondo Y, et al.: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007;104:18654-18659.
11. Graziano F, Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: How much evidence is enough? Ann Oncol 2003; 14:1026-1038.
12. Locker GY, Hamilton S, Harris J, et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327.
13. Markowitz S, Wang J, Myeroff L, et al.: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
14. Duval A, Hamelin R: Mutations at coding repeat sequences in mismatch repair-deficient human cancers: Toward a new concept of target genes for instability. Cancer Res 2002;62:2447-2454.
15. Duval A, Hamelin R: Genetic instability in human mismatch repair deficient cancers. Ann Genet 2002;45:71-75.
16. Vousden KH: Prives C Blinded by the Light: The Growing Complexity of p53. Cell 2009;137:413-431.
17. Cuilliere-Dartigues P, El-Bchiri J, Krimi A, et al.: TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription. Oncogene 2006;25:4441-4448.
18. Raut CP, Pawlik TM, Rodriguez-Bigas MA: Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res 2004;568:275-282.
19. Tejpar S: The multidisciplinary management of gastrointestinal cancer. The use of molecular markers in the diagnosis and treatment of colorectal cancer. Clin Gastroenterol 2007;21:1071-1087.
20. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
21. Benatti P, Gafa R, Barana D, et al.: Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005;11:8332-8340.
22. Chang EY, Dorsey PB, Johnson N, et al.: A prospective analysis of microsatellite instability as a molecular marker in colorectal cancer. Am J Surg 2006;191:646-651.
23. Malesci A, Laghi L, Bianchi P, et al.: Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-3839.
24. Barrasa Shaw A, Lopez-Guerrero JA, Calatrava Fons A, et al.: Value of the identification of microsatellite instability in colorectal cancer. Clin Transl Oncol 2009;11:465-469.
25. Banerjea A, Hands RE, Powar MP, et al.: Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis 2009;11: 601-608.
26. Hutchins G, Southward K, Handley K, et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncology 2011;29:1261-1270.
27. Haddad R, Ogilvie RT, Croitoru M, et al.: Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncology 2004;11:977-982.
28. Evaluation of Genomic Applications in Practice and Prevention Working Group: Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
29. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7: 295-308.
30. US National Library of Medicine: Genetics Home Reference- KRAS. http://ghr.nlm.nih.gov/gene/KRAS. Accessed September 5, 2014.
31. Williams JP, Stewart T, Li B, et al.: The retinoblastoma protein is required for Ras-induced oncogenic transformation. Mol Cell Biol 2006;26:1170-1182.
32. Wellcome Trust Sanger Institute: Catalogue of somatic mutations in cancer. http://www.sanger.ac.uk/genetics/CGP/cosmic. Accessed May 12, 2014.
33. Moerkerk P, Arends JW, Van Driel M, et al.: Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994;54:3376-3378.
34. Cerottini JP, Caplin S, Saraga E, et al.: The type of K-ras mutation determines prognosis in colorectal cancer. Am J Surg 1998;175: 198-202.
35. Poehlmann A, Kuester D, Meyer F, et al.: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007;203:489-497.
36. Abubaker J, Bavi P, Al-Haqawi W, et al.: Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009;219:435-445.
37. Bazan V, Migliavacca M, Zanna I, et al.: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-1446.
38. Bazan VAV, Corsale S, Calo V, et al.: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. J Clin Oncol 2005;23:50-55.
39. Elnatan J, Goh HS, Smith DR: C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Euro J Cancer 1996;32A:491-497.
40. Samowitz WS, Curtin K, Schaffer D, et al.: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prevent 2000;9:1193-1197.
41. Pajkos G, Kiss I, Sandor J, et al.: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 2000;20:1695-1701.
42. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684.
43. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001;85:692-696.
44. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60- 00 trial. J Clin Oncol 2010;28:466-474.
45. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
46. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
47. Ikenoue T, Hikiba Y, Kanai F, et al.: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-8137.
48. Fransen K, Klintenas M, Osterstrom A, et al.: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533.
49. Ogino S, Nosho K, Kirkner GJ, et al.: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
50. Maestro ML, Vidaurreta M, Sanz-Casla MT, et al.: Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol 2007;14:1229-1236.
51. Samowitz WS, Sweeney C, Herrick J, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
52. Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
53. Bokemeyer C, Van Cutsem E, Rougier P, et al.: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wildtype metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Euro J Cancer 2012;48: 1466-1475.
54. Jehan Z, Bavi P, Sultana M, et al.: Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009;219:337-346.
55. Kato S, Iida S, Higuchi T, et al.: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Intl J Cancer 2007;121:1771-1778.
56. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487: 330-337.
57. Ogino S, Nosho K, Kirkner GJ, et al.: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-1484.
58. US National Library of Medicine: Genetics Home Reference- PIK3CA. http://ghr.nlm.nih.gov/gene/PIK3CA. Accessed September 5, 2014.
59. Brocardo M, Henderson BR: APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol 2008;18:587-596.
60. US National Library of Medicine: Genetics Home Reference- APC. http://www.ghr.nlm.nih.gov/gene/APC. Accessed September 5, 2014.
61. Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Develop 2007;17:45-51.
62. Aoki K, Taketo MM: Adenomatous polyposis coli (APC): A multifunctional tumor suppressor gene. J Cell Sci 2007;120:3327-3335.
63. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1998;319: 525-532.
64. Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005;92:434-444.
65. Popat S, Houlston RS: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Euro J Cancer 2005;41:2060-2070.
66. Halling KC, French AJ, Mcdonnell SK, et al.: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
67. Olschwang S, Hamelin R, Laurent-Puig P, et al.: Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A 1997;94:12122-12127.
68. US Nationlal Library of Medicine: Genetics Home Reference- Gene. http://ghr.nlm.nih.gov/gene. Accessed September 5, 2014.
69. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
70. Benson AB 3rd, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
71. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Molec Cell Biol 2001;2:127-137.
72. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
73. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
74. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
75. Jonker DJ, O'callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
76. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
77. Chung KY, Shia J, Kemeny NE, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
78. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
79. Van Cutsem EI, D'haens G, Moiseyenko V, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting 2008;26:May 20 Supplement.
80. Kim KJ, Li B, Winer J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
81. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
82. Poehlmann A, Kuester D, Meyer F, et al.: K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007;203:489-497.
83. Abubaker J, Bavi P, Al-Haqawi W, et al.: Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009;219:435-445.
84. Bazan V, Migliavacca M, Zanna I, et al.: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438-1446.
85. Bazan VAV, Corsale S, Calo V, et al.: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. J Clin Oncol 2005;23:50-55.
86. Elnatan J, Goh HS, Smith DR: C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Euro J Cancer 1996;32A:491-497.
87. Samowitz WS, Curtin K, Schaffer D, et al.: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prevent 2000;9:1193-1197.
88. Pajkos G, Kiss I, Sandor J, et al.: The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 2000;20:1695-1701.
89. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684.
90. Andreyev HJ, Norman AR, Cunningham D, et al.: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001;85:692-696.
91. Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60- 00 trial. J Clin Oncol 2010;28:466-474.
92. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
93. Rajagopalan H, Bardelli A, Lengauer C, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418:934.
94. Ikenoue T, Hikiba Y, Kanai F, et al.: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-8137.
95. Fransen K, Klintenas M, Osterstrom A, et al.: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533.
96. Ogino S, Nosho K, Kirkner GJ, et al.: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
97. Maestro ML, Vidaurreta M, Sanz-Casla MT, et al.: Role of the BRAF mutations in the microsatellite instability genetic pathway in sporadic colorectal cancer. Ann Surg Oncol 2007;14:1229-1236.
98. Samowitz WS, Sweeney C, Herrick J, et al.: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
99. Di Nicolantonio F, Martini M, Molinari F, et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-5712.
100. Bokemeyer C, Van Cutsem E, Rougier P, et al.: Addition of cetuximab to chemotherapy as first-line treatment for KRAS wildtype metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Euro J Cancer 2012;48: 1466-1475.
101. Jehan Z, Bavi P, Sultana M, et al.: Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009;219:337-346.
102. Kato S, Iida S, Higuchi T, et al.: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Intl J Cancer 2007;121:1771-1778.
103. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487: 330-337.
104. Ogino S, Nosho K, Kirkner GJ, et al.: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-1484.
105. US National Library of Medicine: Genetics Home Reference- PIK3CA. http://ghr.nlm.nih.gov/gene/PIK3CA. Accessed September 5, 2014.
106. Brocardo M, Henderson BR: APC shuttling to the membrane, nucleus and beyond. Trends Cell Biol 2008;18:587-596.
107. US National Library of Medicine: Genetics Home Reference- APC. http://www.ghr.nlm.nih.gov/gene/APC. Accessed September 5, 2014.
108. Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Develop 2007;17:45-51.
109. Aoki K, Taketo MM: Adenomatous polyposis coli (APC): A multifunctional tumor suppressor gene. J Cell Sci 2007;120:3327-3335.
110. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1998;319: 525-532.
111. Munro AJ, Lain S, Lane DP: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005;92:434-444.
112. Popat S, Houlston RS: A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Euro J Cancer 2005;41:2060-2070.
113. Halling KC, French AJ, Mcdonnell SK, et al.: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
114. Olschwang S, Hamelin R, Laurent-Puig P, et al.: Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci U S A 1997;94:12122-12127.
115. US Nationlal Library of Medicine: Genetics Home Reference- Gene. http://ghr.nlm.nih.gov/gene. Accessed September 5, 2014.
116. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
117. Benson AB 3rd, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
118. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Molec Cell Biol 2001;2:127-137.
119. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
120. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
121. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
122. Jonker DJ, O'callaghan CJ, Karapetis CS, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
123. Van Cutsem E, Peeters M, Siena S, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
124. Chung KY, Shia J, Kemeny NE, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
125. Amado RG, Wolf M, Peeters M, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
126. Van Cutsem EI, D'haens G, Moiseyenko V, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. ASCO Annual Meeting 2008;26:May 20 Supplement.
127. Kim KJ, Li B, Winer J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
128. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. Journal of Surgical Oncology Molecular Markers for Colon Diagnosis 101
129. Price TJ, Hardingham JE, Lee CK, et al.: Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol 2011;29:2675-2682.
130. Braun MS, Richman SD, Quirke P, et al.: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690-2698.
131. Koopman M, Venderbosch S, Van Tinteren H, et al.: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Euro J Cancer 2009;45:1999-2006.